Vericel Corporation

VCEL ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024
Operating Activities
Net Income $2.2M $-6.3M $23.2M $5.1M $-553.0K $-11.2M $19.8M $-901.0K
Depreciation & Amortization $3.6M $3.3M $3.1M $2.9M $2.8M $2.7M $1.5M $1.3M
Depreciation $3.5M $3.1M $2.9M $2.8M $2.7M $2.5M $1.3M $1.2M
Amortization — — — — — — — —
Stock-Based Compensation $9.1M $11.3M $8.4M $8.7M $10.1M $11.5M $7.9M $9.2M
Net Cash from Operating Activities $16.2M $16.4M $15.0M $22.1M $8.2M $6.6M $22.2M $10.2M
Investing Activities
Capital Expenditures $1.9M $1.3M $2.2M $2.6M $8.1M $14.2M $13.8M $19.4M
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $-2.8M $-4.2M $-16.4M $-3.4M $-9.0M $-15.1M $-14.7M $-21.2M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $2.7M $-3.0M $1.1M $1.2M $1.6M $3.2M $7.1M $5.5M
Net Change in Cash $16.1M $9.2M $-311.0K $19.9M $827.0K $-5.3M $14.7M $-5.5M
Free Cash Flow $14.3M $15.1M $12.8M $19.5M $81.0K $-7.6M $8.5M $-9.2M
← Newer Page 1 of 8 Older →